Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

Hepatocellular carcinoma (HCC) is a lethal malignancy with poor prognosis. More than 80%
of patients are diagnosed at an advanced stage, and most patients with HCC also have liver …

The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

Cases of hepatocellular carcinoma (HCC) are rapidly rising. This is particularly the case in
the Western world, as a result of increasing rates of chronic liver disease, secondary to …

Following the success of immune checkpoint blockers (ICBs) in different cancer types, a
large number of studies are currently investigating ICBs in patients with hepatocellular …

A couple of molecular-targeting medications, such as Lenvatinib, are available for the
treatment of hepatocellular carcinoma (HCC) in addition to Sorafenib in an advanced stage …

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the third
leading cause of cancer-related death worldwide. Single-agent anti-PD-1 immune …

Advanced hepatocellular carcinoma (HCC) is a serious therapeutic challenge and targeted
therapies only provide a modest benefit in terms of overall survival. Novel approaches are …

Immune-checkpoint inhibitors (ICIs) are now widely used for the treatment of patients with
advanced-stage hepatocellular carcinoma (HCC). Two different ICI-containing regimens …